Navigation Links
Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Date:12/9/2008

SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today announced that it has initiated patient enrollment in INNOVATE-PCI, a large Phase II clinical trial of PRT060128, the Company's novel P2Y12 ADP receptor antagonist, in patients undergoing non-urgent percutaneous coronary intervention (PCI).

"With the initiation of our second Phase II trial within a month, we are on track to successfully achieve our company milestones for 2008," said Charles Homcy, M.D., president and chief executive officer of Portola. "With its reversible and competitive properties and intravenous and oral delivery, PRT060128 has the potential for a broader therapeutic window and to become an important anti-platelet therapy in treating thrombosis patients in both the acute and chronic settings."

The Phase II randomized, double-blind, multi-center trial will evaluate the safety, tolerability and efficacy of an intravenous (IV) bolus of PRT060128 followed by one of three doses (50mg, 100mg, 150mg) of the oral formulation of PRT060128 compared to clopidogrel (Plavix(R)) in approximately 800 patients undergoing non-urgent PCI. The study is designed to evaluate multiple endpoints in order to assess dose in relation to clinical efficacy, biological activity, tolerability and safety of PRT060128 during a minimum 60-day treatment phase.

"Despite the prevalence of anti-platelet therapies available today, major adverse cardiac events continue to occur among patients undergoing PCI," said Robert A. Harrington, M.D., study chair and director of the Duke Clinical Research Institute at Duke University Medical Center in Durham, NC. "PRT060128 appears to be a novel, direct acting, reversible anti-platelet agent and we are very interested to see if these p
'/>"/>

SOURCE Portola Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets in Clopidogrel (Plavix(R)) Non-Responders
2. Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008
3. Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
8. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
9. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
10. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
11. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... appointed Interim Chief Executive Officer of the company, effective ... Ken Berger .  "The Board of Directors of ConvaTec ... over the past three years," said Magnus Lundberg ... are confident that the company is well positioned for ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... States Food and Drug Administration ("FDA") said its primary results ... risk of blood clots for women who use drospirenone-containing birth ... safety of Yaz and Yasmin is the subject of approximately ... Pleas Judge Sandra Mazer Moss, Coordinating Judge of the Complex ...
... BEACH, Calif., Sept. 27, 2011 For the third ... InformationWeek 500 annual listing of the nation,s most innovative ... honored for development and implementation of its Treatment ... communities real-time cost estimates specific to their coverage plan, ...
Cached Medicine Technology:FDA Issues Safety Communication Regarding Increased Risk of Blood Clots with Certain Birth Control Pills 2Medical Mutual of Ohio Earns a Spot on 2011 InformationWeek 500 List of Top Technology Innovators Across America 2Medical Mutual of Ohio Earns a Spot on 2011 InformationWeek 500 List of Top Technology Innovators Across America 3
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Helen Harris’ ... in Woodland Hills, California after an 8 year battle ... on Christmas Eve evening in her home in Woodland ... metastatic breast cancer. , As the ... forty years, she pioneered and championed many of today's ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... , THURSDAY, Dec. 1 (HealthDay News) -- Posting ... processing plants on the Internet so it can be viewed ... report released Wednesday. The report is from the National ... advice on challenges facing the United States and the world. ...
... in the levels of two proteins involved in folding, ... destructive brain plaque found in Alzheimer,s disease, researchers report. ... specific positions to unleash their functions. When levels are ... normally dormant BACE1, a protein responsible for beta amyloid ...
... MD, a fourth-year resident in clinical and anatomic ... the highly coveted Resident Leadership Representative Award from ... demonstrating leadership and promoting ASCP membership and resident ... team led by Dr. Martin Kroll, won the ...
... (EGCG)a flavonoid found in green teainhibits the hepatitis C ... in the December issue of Hepatology , a ... Association for the Study of Liver Diseases, suggest that ... reinfection following liver transplantation. HCV infection can ...
... on chromosomes in human cervical cancer cells disrupts DNA ... and kills them more quickly, according to a study ... to like see their laboratory findings published in ... safer, more effective combination therapies for hard-to-treat pediatric brain ...
... December 1, 2011 -- Only 21 percent of surveyed medical ... when and when not to wash their hands in the ... issue of the American Journal of Infection Control , ... in Infection Control and Epidemiology. Three researchers from ...
Cached Medicine News:Health News:Diametric shift in 2 protein levels spurs Alzheimer's plaque accumulation 2Health News:Green tea flavonoid may prevent reinfection with hepatitis C virus following liver transplantation 2Health News:Cancer cells' DNA repair disrupted to increase radiation sensitivity 2Health News:Cancer cells' DNA repair disrupted to increase radiation sensitivity 3Health News:2 out of 3 medical students do not know when to wash their hands 2
... most other EMR,systems require you ... is the only,electronic patient charting,solution ... orthopaedic,workflow. Created around,five specific criteria ... clinic,OrthoPad allows you to see,more ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... EMS provides service to companies in many different ... and restaurants.There are no hidden charges at EMS ... and service are among the lowest in the ... of services ranging from MasterCard/Visa processing to Debit ...
Medicine Products: